There are several pharmaceutical companies in the United States that invest in the discovery and commercialization of drugs intended to treat disorders of the central nervous systems (CNS). Supernus Pharmaceuticals is one of these companies.
Headquartered in Rockville, Maryland, Supernus Pharmaceuticals has more than 20 years of experience in the industry and operates as a specialty pharmaceutical venture. In 2013, the business launched two products that are created as treatments for epilepsy. These medications are Oxtellar XR and Trokendi XR. In addition to these medications, the company has also taken on the challenge of creating novelty therapeutics for the treatment of attention-deficit hyperactivity disorder (ADHD) and depression.
Through their in-licensed technologies, the company is able to create new medications. They have a wide array of known drug compounds that they use to leverage in creating new therapeutics. Supernus Pharmaceuticals competes against the offerings of Neurovance, Neos Therapeutics, Shire plc and Sunovion.
No comments:
Post a Comment